Merck set to launch Tredaptive in international markets

WHITEHOUSE STATION, N.J. Merck & Co. plans to launch a new lipid-modifying drug in international markets later this year, though it remains under investigation in the United States.

The company announced that it would launch Tredaptive (extended-release niacin and laropiprant) by third quarter in Mexico, the United Kingdom, Germany and 36 other countries. The drug also goes by the brand name Cordaptive.

“Merck is pleased that we are now able to supply Tredaptive in approved markets and continue our long-standing commitment to help address unmet medical needs in cardiovascular care,” Merck Research Laboratories franchise head and SVP atherosclerosis and cardiovascular Luciano Rossetti stated.

The drug is designed to treat mixed dyslipidemia and primary hypercholesterolemia.